- Swiss company could offer above-industry growth, analysts say
- Split leaves Novartis focused solely on innovative treatments
Sandoz Group AG, the maker of copycat medicines that was spun off from drugmaker Novartis AG, begins life as a standalone company on Wednesday when its shares start trading on the Swiss stock exchange.
The generics leader will now have more freedom to pursue its own growth strategy to challenge industry stalwarts like Viatris Inc. and Teva Pharmaceutical Industries Ltd.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.